Luciferins

Organic substances found in organisms that generate BIOLUMINESCENCE such as FIREFLY LUCIFERIN that produces light when oxidized to the excited oxyluciferin by the action of the enzyme LUCIFERASE.

Also Known As:

Networked: 114 relevant articles (2 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Lang, Florian: 15 articles (01/2016 - 08/2009)
2.	Jilani, Kashif: 6 articles (04/2012 - 07/2011)
3.	Lupescu, Adrian: 6 articles (04/2012 - 01/2012)
4.	Qadri, Syed M: 6 articles (04/2012 - 11/2009)
5.	Zelenak, Christine: 5 articles (04/2012 - 07/2011)
6.	Faggio, Caterina: 4 articles (01/2015 - 01/2012)
7.	Zbidah, Mohanad: 4 articles (04/2012 - 01/2012)
8.	Föller, Michael: 4 articles (01/2012 - 08/2009)
9.	Huang, Peng: 3 articles (03/2017 - 01/2015)
10.	Liu, Chunxiao: 3 articles (03/2017 - 01/2015)

Related Diseases

1.	Necrosis 03/01/2020 - "Compared with non-pressurized controls, intermittent pressurization led to better perfusion throughout the 14-day experimental period, improved organ viability as indicated by a higher bioluminescence intensity after perfusion with luciferin, and reduced levels of tissue necrosis with better preservation of vascular structures and skeletal muscle nuclei (histologic analyses). "
2.	Glioma (Gliomas) 10/09/2003 - "Using dual substrate/reporter bioluminescence imaging (Fluc: firefly luciferase-luciferin and Rluc: Renilla luciferase-coelenterazine), we tested the efficacy of TRAIL using replication-deficient herpes simplex virus (HSV) type 1 amplicon vectors in gliomas. "
3.	Neoplasms (Cancer) 01/01/2015 - "The analyses of luciferin-stained tumor images 28 days after each treatment showed significant tumor growth inhibition in the high-dose group in comparison with that in the low-dose- or PBS-treated groups. " 11/01/2014 - "Nano-Luc and Nano-LucDiR enhanced plasma half-life of luciferin compared to free luciferin thus providing longer circulation of luciferin in plasma enabling imaging of tumors for more than 24 h. " 01/01/2014 - "Here, we present a new model to allow analysis of average luciferin flux ([Formula: see text]) through the tumor, a more biologically relevant parameter than peak bioluminescence as traditionally measured. " 11/01/2013 - "Tumor growth was assessed qualitatively and noninvasively via bioluminescence emission, upon luciferin injection. " 01/01/2013 - "Importantly, Se-Yeast supplementation decreased the growth of brain metastatic tumors as determined by the measurement of the intensity of the bioluminescent signal emitted by K1735-Luc cells upon reaction with luciferin. "
4.	Photophobia (Light Sensitivity) 10/27/2022 - "This study demonstrates that peripheral delivery of the luciferin CTZ can be used to activate LMOs expressed in spinal cord neurons that employ an opsin with increased light sensitivity."
5.	Hemolysis 01/01/2016 - "In addition cytosolic ATP levels were quantified utilizing a luciferin-luciferase-based assay and hemolysis was estimated from hemoglobin concentration in the supernatant. " 02/10/2010 - "Supernatant hemoglobin concentration was determined to reveal hemolysis, annexin V-binding in FACS analysis was utilized to identify erythrocytes with scrambled cell membrane, forward scatter in FACS analysis was taken as a measure of cell volume, and a luciferin-luciferase assay was employed to determine erythrocyte ATP content. " 08/01/2009 - "Phosphatidylserine exposure was determined by annexin V-binding, cell volume by forward scatter, cellular ATP by a luciferin-luciferase assay kit, and hemolysis by photometry. " 01/01/2015 - "To this end, phosphatidylserine exposure at the cell surface was estimated from annexin-V-binding, cell volume from forward scatter, hemolysis from hemoglobin release, [Ca2+]i from Fluo3-fluorescence, ROS formation from DCFDA dependent fluorescence and cytosolic ATP levels utilizing a luciferin-luciferase-based assay. " 01/01/2012 - "[Ca(2+)](i )was estimated from Fluo-3-fluorescence, cell volume from forward scatter, phosphatidylserine-exposure from annexin-V-binding, hemolysis from hemoglobin release, ceramide abundance from anti-ceramide antibody binding, and cytosolic ATP from luciferin-luciferase activity. "

Related Drugs and Biologics

1.	Firefly Luciferases
2.	Renilla Luciferases
3.	coelenterazine
4.	Luciferases
5.	Adenosine Triphosphate (ATP)
6.	Opsins
7.	D-luciferin
8.	Annexin A5
9.	Hemoglobins (Hemoglobin)
10.	Phosphatidylserines

Related Therapies and Procedures

1.	Subcutaneous Injections
2.	Injections
3.	Induced Hyperthermia (Thermotherapy)
4.	Castration